Nice find by My69z. Here's the link: https:/
Post# of 153345
Here's the link:
https://www.businesswire.com/news/home/202411...ce-Q1-2025
But I think it seems the opposite of the MOA employed in our trial.
"Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group"

